An observational, retrospective, and multicenter study depicted that non-alcoholic fatty liver disease (NAFLD) is strongly linked with a greater prevalence of decreased estimated glomerular filtration rate (eGFR) in people having moderate-to-severe chronic plaque psoriasis, independent of cardiometabolic risk factors and psoriasis-associated variables such as psoriasis severity and psoriatic arthritis.

Francesco Bellinato et al. performed this study to determine if ultrasound-diagnosed NAFLD is linked with impaired renal function in 337 people suffering from psoriasis. The recruited subjects had no history of excessive alcohol drinking or other secondary causes of chronic hepatic and kidney diseases. Using ultrasonography, diagnosis of NAFLD was done. Chronic kidney disease (CKD) stage ≥2 was defined by an e-GFR of <90 ml min-1 1.73 m-2 while CKD stage ≥3 was defined by an e-GFR of <60 ml min-1 1.73 m-2.

For evaluating the independent link of NAFLD with CKD or eGFR levels, logistic and linear regression assessments were performed. Individuals having NAFLD (n = 212, 62.9% of total) had substantially reduced e-GFR levels and a considerably greater prevalence of both CKD stage ≥2 and CKD stage ≥3 in comparison with people without NAFLD, as illustrated in Table 1:

As per the multivariable logistic regression assessment, NAFLD was linked with a nearly 2.5-fold elevated risk of prevalent CKD stage ≥2 (adjusted-odds ratio= 2.60), independently of components of metabolic syndrome, psoriatic arthritis, and psoriasis severity.